188 related articles for article (PubMed ID: 293141)
1. Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation.
Chang AE; Shiling DJ; Stillman RC; Goldberg NH; Seipp CA; Barofsky I; Simon RM; Rosenberg SA
Ann Intern Med; 1979 Dec; 91(6):819-24. PubMed ID: 293141
[TBL] [Abstract][Full Text] [Related]
2. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy.
Chang AE; Shiling DJ; Stillman RC; Goldberg NH; Seipp CA; Barofsky I; Rosenberg SA
Cancer; 1981 Apr; 47(7):1746-51. PubMed ID: 6261926
[TBL] [Abstract][Full Text] [Related]
3. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.
Frytak S; Moertel CG; O'Fallon JR; Rubin J; Creagan ET; O'Connell MJ; Schutt AJ; Schwartau NW
Ann Intern Med; 1979 Dec; 91(6):825-30. PubMed ID: 517882
[TBL] [Abstract][Full Text] [Related]
4. Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis.
Orr LE; McKernan JF; Bloome B
Arch Intern Med; 1980 Nov; 140(11):1431-3. PubMed ID: 6254456
[TBL] [Abstract][Full Text] [Related]
5. Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine.
Orr LE; McKernan JF
J Clin Pharmacol; 1981; 21(S1):76S-80S. PubMed ID: 6271846
[TBL] [Abstract][Full Text] [Related]
6. Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy.
Treish I; Shord S; Valgus J; Harvey D; Nagy J; Stegal J; Lindley C
Support Care Cancer; 2003 Aug; 11(8):516-21. PubMed ID: 12836088
[TBL] [Abstract][Full Text] [Related]
7. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study.
McCallum RW; Soykan I; Sridhar KR; Ricci DA; Lange RC; Plankey MW
Aliment Pharmacol Ther; 1999 Jan; 13(1):77-80. PubMed ID: 9892882
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
Smith DB; Newlands ES; Rustin GJ; Begent RH; Howells N; McQuade B; Bagshawe KD
Lancet; 1991 Aug; 338(8765):487-90. PubMed ID: 1714532
[TBL] [Abstract][Full Text] [Related]
9. Use of propofol for the prevention of chemotherapy-induced nausea and emesis in oncology patients.
Scher CS; Amar D; McDowall RH; Barst SM
Can J Anaesth; 1992 Feb; 39(2):170-2. PubMed ID: 1544199
[TBL] [Abstract][Full Text] [Related]
10. Comparative trial of the antiemetic effects of THC and haloperidol.
Neidhart JA; Gagen MM; Wilson HE; Young DC
J Clin Pharmacol; 1981; 21(S1):38S-42S. PubMed ID: 6271838
[TBL] [Abstract][Full Text] [Related]
11. In search of an effective antiemetic: a nusring staff participates in marijuana research.
Seipp CA; Chang AE; Shiling DJ; Rosenberg SA
Cancer Nurs; 1980 Aug; 3(4):271-6. PubMed ID: 6249493
[No Abstract] [Full Text] [Related]
12. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy.
McCabe M; Smith FP; Macdonald JS; Woolley PV; Goldberg D; Schein PS
Invest New Drugs; 1988 Sep; 6(3):243-6. PubMed ID: 2847994
[TBL] [Abstract][Full Text] [Related]
13. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol.
Ekert H; Waters KD; Jurk IH; Mobilia J; Loughnan P
Med J Aust; 1979 Dec; 2(12):657-9. PubMed ID: 231736
[TBL] [Abstract][Full Text] [Related]
14. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy.
Sallan SE; Zinberg NE; Frei E
N Engl J Med; 1975 Oct; 293(16):795-7. PubMed ID: 1099449
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
16. Intravenous Delta-9-Tetrahydrocannabinol to Prevent Postoperative Nausea and Vomiting: A Randomized Controlled Trial.
Kleine-Brueggeney M; Greif R; Brenneisen R; Urwyler N; Stueber F; Theiler LG
Anesth Analg; 2015 Nov; 121(5):1157-64. PubMed ID: 26426861
[TBL] [Abstract][Full Text] [Related]
17. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
18. delta 9-Tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancerchemotherapy; a double-blind cross-over trial against placebo.
Kluin-Neleman JC; Neleman FA; Meuwissen OJ; Maes RA
Vet Hum Toxicol; 1979 Oct; 21(5):338-40. PubMed ID: 516362
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron.
Holdsworth MT; Raisch DW; Winter SS; Chavez CM
Support Care Cancer; 1998 Mar; 6(2):132-8. PubMed ID: 9540172
[TBL] [Abstract][Full Text] [Related]
20. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
